A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Phase 2 Terminated
11 enrolled 10 charts
SOLAR
Phase 3 Terminated
530 enrolled 25 charts
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 2 Terminated
26 enrolled 7 charts
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
Phase 3 Terminated
41 enrolled
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Phase 1 Terminated
20 enrolled 18 charts
IRENE
Phase 2 Terminated
21 enrolled
Sindas
Phase 3 Terminated
200 enrolled
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Phase 2 Terminated
19 enrolled 4 charts
NeoIntercal
Phase 2/3 Terminated
1 enrolled
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
Phase 2 Terminated
3 enrolled
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 2 Terminated
38 enrolled 8 charts
TIDAL1
Phase 2 Terminated
32 enrolled
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Phase 2 Terminated
50 enrolled 5 charts
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Phase 1/2 Terminated
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Phase 3 Terminated
270 enrolled 8 charts
IUCRO-0021
Phase 2 Terminated
21 enrolled
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
Phase 2 Terminated
30 enrolled
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 4 Terminated
14 enrolled 12 charts
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
Phase 2 Terminated
1 enrolled
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Phase 2 Terminated
15 enrolled
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
Phase 1/2 Terminated
10 enrolled
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase 1 Terminated
30 enrolled
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Phase 2 Terminated
50 enrolled
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Phase NA Terminated
42 enrolled 3 charts
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 3 Terminated
598 enrolled
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
Phase 3 Terminated
490 enrolled
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
Phase 2 Terminated
47 enrolled
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
Phase 1/2 Terminated
34 enrolled
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Phase 1/2 Terminated
29 enrolled